Proferrin Shortage: What Providers and Prescribers Need to Know in 2026

Providers who routinely recommend Proferrin (heme iron polypeptide) for patients with iron deficiency anemia, GI-intolerant iron needs, or chronic kidney disease are increasingly hearing from patients who cannot find it at their local pharmacy. This article provides a clinical overview of the current availability landscape, evidence-based alternatives, and strategies for minimizing treatment gaps for your patients in 2026.

Clinical Context: Why Proferrin Is Recommended

Proferrin (heme iron polypeptide, or HIP) is derived from bovine hemoglobin through proteolytic digestion. Its distinguishing feature is its absorption pathway: heme iron is transported via the heme carrier protein 1 (HCP1) transporter, distinct from the divalent metal transporter 1 (DMT1) pathway used by ionic iron salts. This has two practical clinical implications:

Reduced competitive inhibition: Heme iron absorption is not significantly affected by calcium, tannins, phytates, PPIs, or achlorhydria — factors that substantially reduce non-heme iron bioavailability.

Lower GI side effect burden: Because Proferrin delivers only 10.5–12 mg of elemental iron per dose (versus 65 mg in standard ferrous sulfate), and uses a different absorptive pathway, the rate of GI adverse effects is lower — improving patient compliance.

Proferrin is particularly well-suited for patients on PPIs, those with achlorhydria, patients with IBS or IBD who cannot tolerate higher-dose ionic iron, pregnant patients experiencing morning sickness, dialysis patients requiring oral iron adjuncts, and athletes with increased iron turnover.

Current Availability Status (2026)

Proferrin is not listed on the FDA Drug Shortage Database, as it is classified as a dietary supplement rather than a prescription drug. However, because it is manufactured exclusively by Colorado Biolabs in the United States, and is not prioritized by major pharmacy chains for consistent shelf allocation, patient-facing availability is frequently inconsistent.

The most reliable retail distribution for Proferrin in 2026 is through online channels: Amazon (Proferrin ES and Forte in 30- and 90-count bottles) and the manufacturer's website (Proferrin.com). Brick-and-mortar availability varies significantly by geographic market.

Evidence Base for Proferrin

Providers should be aware that the clinical evidence for Proferrin (heme iron polypeptide) is promising but limited in scale. Key data points:

A study in 14 healthy subjects demonstrated that heme iron polypeptide increased serum iron levels approximately 23 times greater than an equivalent dose of ferrous fumarate on a milligram-per-milligram basis.

The HEMATOCRIT trial (RCT, peritoneal dialysis patients) found that HIP did not achieve non-inferiority to ferrous sulfate in correcting anemia among darbepoetin-treated PD patients, with ferrous sulfate producing higher ferritin levels at 6 months.

A single-blind RCT in non-dialysis CKD patients found HIP had similar efficacy to IV iron sucrose in maintaining hemoglobin, but was inferior in correcting serum ferritin.

In a 37-patient hemodialysis cohort treated for 6 months, constipation occurred in only 8% of patients — significantly lower than typical rates with ferrous sulfate (30–40%).

Bottom line: Proferrin is appropriate as a second-line option for patients with documented GI intolerance to standard iron formulations, or for specific populations where absorption through the HCP1 pathway is advantageous (PPI users, achlorhydric patients). It should not replace ferrous sulfate as first-line therapy for most IDA cases where standard iron is tolerated.

Therapeutic Alternatives When Proferrin Is Unavailable

When Proferrin is unavailable and the patient cannot tolerate ferrous sulfate or ferrous fumarate, consider the following alternatives in order of GI tolerability:

Ferrous bisglycinate chelate (25–36 mg elemental iron): Best-tolerated non-heme oral iron; 70–80% fewer GI side effects than ferrous sulfate. Available OTC. Appropriate for IBS, pregnancy, IBD patients in remission.

Iron polysaccharide complex (150 mg; Niferex, FeraMAX): Slow-release formulation; well tolerated for chronic supplementation. May require prescription.

Ferrous gluconate (36 mg elemental iron per tablet): Gentler than ferrous sulfate due to lower elemental iron content per tablet. Widely available OTC; inexpensive. Works for patients with mild GI sensitivity.

IV iron (Feraheme, Injectafer, Venofer, Monoferric): Reserve for patients with severe IDA, malabsorption (post-bariatric, celiac, active IBD), CKD on ESA therapy, or documented failure of all oral iron formulations. Rapidly corrects iron stores; requires infusion clinic access.

Patient Counseling When Proferrin Is Unavailable

When counseling patients who can't find Proferrin, providers should emphasize:

The difference between no supply (supplement) and a clinical shortage (FDA-tracked) — helps set accurate expectations.

Online ordering via Amazon or Proferrin.com is typically reliable for 1–2 day shipping.

Ferrous bisglycinate is a viable bridge therapy. If switching, advise a lower elemental iron dose initially to assess GI tolerance.

For pregnant patients, the Proferrin Forte variant (with folic acid) should not be discontinued without a substitute that includes folate supplementation.

Helping Your Patients Access Proferrin Faster

For providers who want to reduce the burden on their staff, medfinder for providers offers a service that calls pharmacies in a patient's area to locate medications in stock, then texts the patient results. This can reduce time spent on pharmacy follow-up calls, especially for specialty supplements like Proferrin that have inconsistent retail availability.

See our complementary provider guide: How to help your patients find Proferrin in stock.